Kilannin Krysiak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5410734/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics, 2012, 44, 53-57.	21.4	513
2	CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nature Genetics, 2017, 49, 170-174.	21.4	460
3	DCIdb 2.0: mining clinically relevant drug–gene interactions. Nucleic Acids Research, 2016, 44, D1036-D1044.	14.5	359
4	Optimizing Cancer Genome Sequencing and Analysis. Cell Systems, 2015, 1, 210-223.	6.2	174
5	Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation. Journal of the American Chemical Society, 2009, 131, 5153-5162.	13.7	159
6	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood, 2017, 129, 473-483.	1.4	147
7	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood, 2018, 131, 182-190.	1.4	130
8	Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nature Communications, 2018, 9, 3787.	12.8	112
9	A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nature Genetics, 2020, 52, 448-457.	21.4	104
10	The prognostic effects of somatic mutations in ER-positive breast cancer. Nature Communications, 2018, 9, 3476.	12.8	89
11	Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice. Blood, 2011, 117, 1530-1539.	1.4	72
12	Standard operating procedure for somatic variant refinement of sequencing data with paired tumor andÂnormal samples. Genetics in Medicine, 2019, 21, 972-981.	2.4	67
13	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 6823-6832.	7.0	66
14	Lipophilic Pyridinium Bisphosphonates: Potent γ <i>δ</i> T Cell Stimulators. Angewandte Chemie - International Edition, 2010, 49, 1136-1138.	13.8	63
15	Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genetics in Medicine, 2022, 24, 986-998.	2.4	55
16	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Experimental Hematology, 2016, 44, 603-613.	0.4	44
17	Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. Bone, 2017, 101, 145-155.	2.9	37
18	Text-mining clinically relevant cancer biomarkers for curation into the CIViC database. Genome Medicine, 2019, 11, 78.	8.2	35

KILANNIN KRYSIAK

#	Article	IF	CITATIONS
19	Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells. PLoS ONE, 2017, 12, e0170470.	2.5	23
20	Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3â€2-azido, 3â€2-deoxythymidine: A QSAR investigation. Bioorganic and Medicinal Chemistry, 2008, 16, 8959-8967.	3.0	22
21	Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. Cell Reports, 2016, 17, 249-260.	6.4	21
22	A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation. Cell Reports, 2019, 28, 1526-1537.e4.	6.4	19
23	Phase 1/dose expansion trial of brentuximab vedotin andÂlenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood, 2022, 139, 1999-2010.	1.4	17
24	Standard operating procedure for curation and clinical interpretation of variants in cancer. Genome Medicine, 2019, 11, 76.	8.2	16
25	Activity of Sulfonium Bisphosphonates on Tumor Cell Lines. Journal of Medicinal Chemistry, 2007, 50, 6067-6079.	6.4	15
26	Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells. Experimental Hematology, 2015, 43, 319-330.e10.	0.4	15
27	Adapting crowdsourced clinical cancer curation in CIViC to the ClinGen minimum variant level data communityâ€driven standards. Human Mutation, 2018, 39, 1721-1732.	2.5	15
28	CIViCpy: A Python Software Development and Analysis Toolkit for the CIViC Knowledgebase. JCO Clinical Cancer Informatics, 2020, 4, 245-253.	2.1	10
29	Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes. JCO Clinical Cancer Informatics, 2019, 3, 1-12.	2.1	6
30	Large scale genotype―and phenotypeâ€driven machine learning in Von Hippelâ€Lindau disease. Human Mutation, 2022, 43, 1268-1285.	2.5	6
31	Haploinsufficiency of multiple del(5q) genes induce B cell abnormalities in mice. Leukemia Research, 2020, 96, 106428.	0.8	5
32	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. JCO Precision Oncology, 2021, 5, 191-203.	3.0	4
33	Heterozygous <scp><i>HMGB1</i></scp> lossâ€ofâ€function variants are associated with developmental delay and microcephaly. Clinical Genetics, 2021, 100, 386-395.	2.0	3
34	Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers. Cancer Genetics, 2022, 264-265, 90-99.	0.4	3
35	A community approach to the cancer-variant-interpretation bottleneck. Nature Cancer, 2022, 3, 522-525.	13.2	3
36	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. Blood, 2015, 126, 574-574.	1.4	2

#	Article	IF	CITATIONS
37	Exome Sequencing of Hodgkin's and Non-Hodgkin Composite Lymphomas Identifies Shared Somatic Mutations Indicative of Common Founding Precursors. Blood, 2016, 128, 5285-5285.	1.4	0
38	Deleterious Germline Mutations in Telomere Maintenance Genes Identified in a Subset of Patients with Myelodysplastic Syndrome and Idiopathic Pulmonary Fibrosis. Blood, 2016, 128, 4306-4306.	1.4	0
39	Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). Blood, 2020, 136, 23-23.	1.4	Ο